Capricor Therapeutics, Inc. (CAPR)

NMS – Real Time Price. Currency in USD

26.44

-3.96 (-13.03%)

At close: Jun 26, 2026, 4:00 PM EDT

26.83

+0.39 (1.48%)

After-hours: Jun 26, 2026, 7:53 PM EDT

12.06.2026

Caprock Announces Proposed Private Placement

Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce a proposed non-brokered private placement offering of up to 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of up to $600,000 (the "Offering"). The Company may, in its discretion and subject to the approval of the Canadian Securities Exchange (the "CSE"), increase the size of the Offering.

12.06.2026

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce high-grade assay results for the final three drill holes from the recently concluded deep drilling campaign at its flagship Destiny gold property ("Destiny", or the "Property", or the "Project"), located near Val d'Or, Quebec. Key Assay Highlights from the Final 3 Deep Drill Holes: DES-26-184W1: Intersected 8.32 g/t Au over 2.6m and 6.43 g/t Au over 1.8m.

11.06.2026

Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy

Capricor Therapeutics NASDAQ: CAPR executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy.

10.06.2026

Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

08.06.2026

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.

03.06.2026

Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis

Capricor is rated a speculative Buy ahead of its August 22 PDUFA for deramiocel in Duchenne muscular dystrophy. Recent HOPE-3 data disclosures address most prior concerns about primary and cardiac endpoints, reducing trial-related risks. Key remaining risks include commercial disputes with NS Pharma/Nippon Shinyaku and limited initial manufacturing capacity.

13.05.2026

Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

12.06.2026

Caprock Announces Proposed Private Placement

12.06.2026

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

12.05.2026

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints GMP manufacturing facility fully operational; second-floor expansion well underway Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffected Cash balance of approximately $279 million expected to support operations into Q4 2027 Eligible for a Priority Review Voucher upon approval; PRV is transferable and monetizable, offering potential non-dilutive capital Conference call and webcast today at 4:30 p.m.

12.03.2026

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update.

Capricor Therapeutics, Inc. (CAPR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Capricor Therapeutics, Inc. (CAPR)

Caprock Announces Proposed Private Placement

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy

Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Capricor Therapeutics to Present at Upcoming Investor Conferences

Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis

Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Caprock Announces Proposed Private Placement

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Caprock Announces Proposed Private Placement

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy

Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Capricor Therapeutics to Present at Upcoming Investor Conferences

Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis

Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Caprock Announces Proposed Private Placement

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Search stocks

Capricor Therapeutics, Inc. (CAPR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Capricor Therapeutics, Inc. (CAPR)

Caprock Announces Proposed Private Placement

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy

Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Capricor Therapeutics to Present at Upcoming Investor Conferences

Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis

Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Caprock Announces Proposed Private Placement

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Caprock Announces Proposed Private Placement

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy

Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Capricor Therapeutics to Present at Upcoming Investor Conferences

Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis

Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Caprock Announces Proposed Private Placement

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update